Overview
Beckley Psytech is a UK-based clinical-stage company developing short-duration psychedelic therapies, with a lead program using intranasal psilocybin (BPL-003) for treatment-resistant depression intended to reduce session time versus oral formulations. They are part of the Beckley Foundation's broader mission to advance psychedelic science.
More in Psychedelics
Latest industry news
Flourish Emerges from Stealth with Bezos and Google Ventures Backing to Target Brain Health
2026-07-11 · Funding
BrainCo Pushes to Commercialize Brain-Tech as China's BCI Ambitions Come Into Focus
2026-07-10 · Industry
FDA Clears PoNS Device for Stroke Rehabilitation, Broadening Neurostimulation's Clinical Reach
2026-07-09 · Policy
Neurovalens Wins FDA Approval for PTSD Therapy Targeting US Veterans
2026-07-08 · Policy
Company details
Category
🍄 Psychedelics
Location
Oxford, UK
Funding
Series B · $80M
Website
www.beckleypsytech.comListed
2026-06-15
Is this your company?
Claim this listing to add your logo, full description, team, and products. Premium listings get featured placement.
Claim & upgrade listingAdvertise
Reach neurotech professionals
Newsletter sponsorships, featured listings, and sponsored articles.
View packages →